🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

RecruitingPhase 3Ages 18 Years - anyAllMahidol University
NCT06850454 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin * age of \>18 years old Exclusion Criteria: * pregnancy or breast feeding * has emetic episode within 24 hours * gut obstruction * uncontrolled brain metastasis * allergy to or current use of olanzapine * concomittant moderate or high emetogenic chemotherapy on day 2-5 * Total bilirubin \> 2 mg/dl or creatinine clearance \< 30 ml/min * unable to swallow drug
💊

What it tests

  • olanzapine
  • Placebo
📍

Where

1 site
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy